Travere Therapeutics (TVTX) Research & Development (2016 - 2025)
Historic Research & Development for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $51.9 million.
- Travere Therapeutics' Research & Development rose 40.83% to $51.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.2 million, marking a year-over-year decrease of 230.84%. This contributed to the annual value of $217.5 million for FY2024, which is 1122.25% down from last year.
- Latest data reveals that Travere Therapeutics reported Research & Development of $51.9 million as of Q3 2025, which was up 40.83% from $49.4 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Research & Development ranged from a high of $66.5 million in Q2 2023 and a low of $46.9 million during Q1 2025
- Over the past 5 years, Travere Therapeutics' median Research & Development value was $54.3 million (recorded in 2024), while the average stood at $54.9 million.
- Per our database at Business Quant, Travere Therapeutics' Research & Development soared by 6825.92% in 2021 and then plummeted by 1829.09% in 2024.
- Over the past 5 years, Travere Therapeutics' Research & Development (Quarter) stood at $53.0 million in 2021, then rose by 9.6% to $58.1 million in 2022, then grew by 2.86% to $59.7 million in 2023, then grew by 3.88% to $62.1 million in 2024, then fell by 16.4% to $51.9 million in 2025.
- Its Research & Development stands at $51.9 million for Q3 2025, versus $49.4 million for Q2 2025 and $46.9 million for Q1 2025.